Active Ingredient(s): Pegloticase
FDA Approved: * September 14, 2010
Pharm Company: * SAVIENT PHARMS
Category: Gout

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Krystexxa Overview

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated.[1] The drug is administered by infusion intravenously. It was developed by Savient Pharmaceuticals.[2][3] It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid cryst...

Read more Krystexxa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Krystexxa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 8mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Krystexxa: (3 results)

Sorted by National Drug Code
  • 54396-801 Krystexxa 8 mg/ml Intravenous Injection, Solution by Savient Pharmaceuticals, Inc.
  • 60809-801 Krystexxa 8 mg/ml Intravenous Injection, Solution by Crealta Pharmaceuticals LLC
  • 75987-080 Krystexxa 8 mg/ml Intravenous Injection, Solution by Horizon Pharma Inc.

Other drugs which contain Pegloticase or a similar ingredient: (1 result)